PEGBIO
Founded in 2008, Suzhou city-based PegBio is a bio-pharmaceutical company specializing in the development of innovative drugs to combat diabetes and obesity. Its key product PB-119, an agonist of glucagon-like peptide 1 (GLP-1), allows diabetes patients to take medicine once a week, instead of requiring daily injections.
PEGBIO
Industry:
Health Care Pharmaceutical
Founded:
2008-01-01
Address:
Suzhou, Jiangsu, China
Country:
China
Website Url:
http://www.pegbio.com
Total Employee:
11+
Status:
Active
Contact:
0512-62956128
Email Addresses:
[email protected]
Total Funding:
23.1 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Content Delivery Network Mobile Non Scaleable Content ASP.NET Apple Mobile Web App Capable Apple Mobile Web App Status Bar Style China Telecom Bootcss Micro_httpd
Similar Organizations
DrugStoc
DrugStoc is an innovative drug procurement platform.
Purple Biotech
Purple Biotech is an innovative biopharmaceutical drug development company.
Virogin Biotech
Virogin Biotech is an antineoplastic drug developer.
Current Employees Featured
Founder
Investors List
Tasly Holding Group
Tasly Holding Group investment in Series E - PegBio
Legend Capital
Legend Capital investment in Series D - PegBio
ShareLink Capital
ShareLink Capital investment in Series D - PegBio
Mingxin China Growth Fund
Mingxin China Growth Fund investment in Series C - PegBio
Oriza Seed Capital (Oriza Yuandian)
Oriza Seed Capital (Oriza Yuandian) investment in Series C - PegBio
Cowin Venture
Cowin Venture investment in Series B - PegBio
Legend Star
Legend Star investment in Series A - PegBio
Official Site Inspections
http://www.pegbio.com
- Host name: 59.56.106.142
- IP address: 59.56.106.142
- Location: China
- Latitude: 24.4798
- Longitude: 118.0819
- Timezone: Asia/Shanghai
More informations about "PegBio"
PegBio - Crunchbase Company Profile & Funding
Founded in 2008, Suzhou city-based PegBio is a bio-pharmaceutical company specializing in the development of innovative drugs to combat diabetes and obesity. Its key product PB-119, an โฆSee details»
PegBio
Founded in 2008, we are a biotechnology company focused on the in-house discovery and development of innovative therapies for chronic diseases with a particular emphasis on metabolic disorders.See details»
PegBio
Cds 2024 | ๅฟซ้่ตทๆ๏ผๅฎ็จณๅ่กโโๆฐๅ glp-1 ra ๅจๅถๅๅผ้ข t2dm ๆฒป็ๆฐๆถไปฃSee details»
PegBio Company Profile 2024: Valuation, Funding
PegBio General Information Description. Developer of a biopharmaceutical drug discovery firm in China. The company's research specializes in the research and development of type 2 diabetes, nonalcoholic fatty liver, gout, cardiovascular โฆSee details»
PegBio - Products, Competitors, Financials, Employees, โฆ
About PegBio. PegBio is a biopharmaceutical company focused on the innovation and production of drugs for chronic disease treatment. The company develops innovative drugs targeting โฆSee details»
PegBio Company Profile - Office Locations, Competitors, Revenue โฆ
PegBio is a biopharmaceutical company specializing in manufacturing polyethylene glycol and development of PEGylation technology leading to PEGylated drugs as putative NEW Molecule โฆSee details»
PegBio - Funding, Financials, Valuation & Investors - Crunchbase
How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead Investors . Access exclusive financial โฆSee details»
PegBio - VentureRadar
" PegBio is a leading biopharmaceutical company in China, specializing in manufacturing polyethylene glycol (PEG) and development of PEGylation technology leading to PEGylated โฆSee details»
PegBio - Contacts, Employees, Board Members, Advisors & Alumni โฆ
Organization. PegBio . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 1. About. PegBio has 1 โฆSee details»
Chinese biopharma firm developing diabetes drugs ... - The China โฆ
Dec 7, 2020 Pegbio will use the latest funding to promote its drugsโ global clinical trials, support drug R&D, and introduce licensed drugs from overseas to the Chinese market. Pegbioโs โฆSee details»
PegBio
Collaboration on technical platform. We have established a Highly Effective Target Screening & Molecule Modifier Platform (HECTOR®). Through HECTOR®, we leverage our sophisticated โฆSee details»
Chinese Biopharma Firm Pegbio Nets $122m in Pre-IPO Round โฆ
Dec 2, 2020 Pegbio, a Suzhou-based biopharmaceutical company that specialises in innovative drugs for diabetes and obesity, announced on Tuesday that it has secured around 800 million โฆSee details»
PegBio aims to bulk up its finances to deliver weight-loss drugs
Nov 21, 2024 PegBio addressed the market challenge in its prospectus, saying PB-119 will face 13 competitors for the treatment of Type 2 diabetes and more than 15 for obesity in China โฆSee details»
Chinese diabetes-focused biotech Pegbio plans Hong Kong IPO
Mar 13, 2024 Chinaโs Pegbio Co. Ltd. is planning a Hong Kong IPO to advance PB-119, its main glucagon-like peptide 1 receptor agonist for diabetes nearing domestic approval, as it hopes to โฆSee details»
Pegbio Raises $122 Million in Pre-IPO Round for Pegylated Drugs
Dec 7, 2020 Pegbio, a Suzhou biopharma, completed a $122 million financing to support its novel long-acting treatments prior to a planned IPO on Shanghai's STAR market. Founded in โฆSee details»
PB-1902 - Drug Targets, Indications, Patents - Synapse
Nov 21, 2024 PB-1902: a ฮผ opioid receptor antagonists Drug, Initially developed by PegBio Co., Ltd., Now, its global highest R&D status is Phase 1, Mechanism: ฮผ opioid receptor โฆSee details»
Efficacy and safety of PEGylated exenatide injection (PB-119) in ...
ClinicalTrials.gov NCT03520972 FUNDING: The study was funded by National Major Scientific and Technological Special Project for Significant New Drugs Development and PegBio. โฆSee details»
PegBio Plans Hong Kong IPO to Support Long Acting GLP-1 for โฆ
Mar 14, 2024 PegBio, a Suzhou biotech, has filed for a Hong Kong IPO to support commercialization of its long-acting pegylated GLP-1 receptor agonist for type 2 diabetes and โฆSee details»
China's PegBio Selects LifeSphere by ArisGlobal for Safety Case โฆ
Oct 27, 2022 PegBio selected LifeSphere MultiVigilance, a flagship product within the market-leading safety product line, to transition its pharmacovigilance from Contract Research โฆSee details»
PegBio IPO Preview: A Founder-Led Biopharma Player
Mar 11, 2024 PegBio Watchlist. PegBio IPO Preview: A Founder-Led Biopharma Player Fighting T2DM and Obesity in China. Equity Capital Markets. 339 Views11 Mar 2024 02:27. PegBio, a โฆSee details»